Sep 29, 2016

ReadCoor will commercialize the Wyss Institute’s (FISSEQ) fluorescent in situ RNA sequencing technology

Posted by in categories: biotech/medical, business, engineering, neuroscience

Boston-based startup completes $23 million Series A financing to leverage novel imaging platform of gene locations towards gaining diagnostic insights and delivering therapeutics for cancer, immuno-oncology, infectious diseases, neurological and neuromuscular diseases, brain function and cognitive disorders

BOSTON—()—ReadCoor, Inc., today announced completion of an oversubscribed $23 million Series A financing round and its concurrent launch from Harvard University’s Wyss Institute for Biologically Inspired Engineering. ReadCoor will commercialize the Wyss Institute’s FISSEQ (fluorescent in situ sequencing) technology.

Read more

Comments are closed.